Research programme: influenza virus therapy - ViraBiotech
Alternative Names: FluProLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator ViraBiotech
- Class Viruses
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (Intranasal)
- 09 Jan 2008 Preclinical trials in Influenza virus infections in United Kingdom (Intranasal)